Mechanistically, miR-17-92 promotes effector differentiation by targeting multiple tumor suppressors, including PTEN, thereby relieving the inhibition of the PI3K-AKT-mTOR axis and driving metabolic reprogramming toward glycolysis and protein synthesis, which are required for rapid cell division and cytotoxic effector functions [84]. Here, AKT1 is linked to neoplasm.